Programme Overview
An annual programme to educate and support early stage medtech businesses.
About the programme
Programme Overview
Led by Imperial College London, MedTech SuperConnector (MTSC) provides funding, training, advice and access to industry networks. The accelerator programme allows Early Career Researchers (ECRs) to connect with peers from other academic institutions and the networking opportunities they need to help fast-track the translation of their research discoveries.
We are a warm, open and encouraging community that offers researchers, academics and entrepreneurs the support and stimulation they need to turn their medtech ideas into businesses. Running annual accelerator programme intakes throughout the year, we’re always open to hearing from the next wave of medtech innovators.
We have supported over 34 ventures and 65+ ECRs to bring their innovative medical technologies closer to solving today’s biggest healthcare challenges. Covering innovations in skin health to handheld diagnostics – we support technologies ranging from devices to digital healthcare solutions.
Our impact
ECRs supported from 8 HEIs
New medtech sector employment opportunities
Pilot Programmes & Partnerships signed
Technologies progressed towards clinical & user trials
Programme Structure
Programme Structure
Entrepreneurial Learning
We offer a number of educational opportunities that we have developed for remote learning as well as face-to-face.
Venture Funding
Funding for consumables, prototype development and access to specialist advice along with travel & conference fees.
Expert Networks
As a programme participant, you’ll have access to domain experts, industry-specific support and networking opportunities.
Workshops
Starting with a bootcamp, we run a series of masterclasses throughout each programme – covering topics such as intellectual property, regulatory strategy to market access and funding.
PI Benefits
Venture funding is awarded directly to the lab. MedTech SuperConnector does not take IP.
Showcase
Venture teams will have the opportunity to present their ideas and demonstrate the impact of their research to early stage investors and academic partners.
